Bayer Expects Big Gains In APAC With Late-stage Pipeline And Zydus Cadila Joint Venture
This article was originally published in PharmAsia News
Bayer expects half of its 43 clinical trials to be ready for the market in the next few years in Southeast Asia.
You may also be interested in...
Bayer is increasing its holding in its long-standing joint venture with Zydus Cadila in India by 25%, sparking off some speculation on the alliance’s future trajectory.
MUMBAI - A deal that has been brewing for nearly two years has finally taken a concrete shape. Germany's Bayer Healthcare and India's Zydus Cadila have agreed to form an equal stake company that will see Bayer move its existing sales and marketing business in India to the new enterprise
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.